Bone News and Research

RSS

Landmark revascularization procedure

The People's Hospital of Beijing University performed a combined revascularization procedure utilizing beating heart bypass surgery, along with transmyocardial revascularization and stem cell implantation.

13 Dec 2004

Silent risk of osteoporosis in men with prostate cancer

Men being treated for prostate cancer using hormone therapy maybe under-recognized for their risk of developing osteoporosis, according to a new study.

13 Dec 2004

Cell replacement therapy offers a novel and powerful medical technology

Cell replacement therapy offers a novel and powerful medical technology. A type of embryonic stem cell, called a neural crest stem cell, that persists into adulthood in hair follicles was recently discovered by Maya Sieber-Blum, Ph.D., of the Medical College of Wisconsin, Milos Grim, MD Ph.D., of Charles University Prague, and their collaborators.

13 Dec 2004

Helping to heal complications from spinal cord injury

A London scientist has received a major grant to help improve the quality of life for individuals with spinal cord injuries.

8 Dec 2004

Resveratrol antioxidant found in red wine may benefit heart tissue

New research on rat heart cells suggests that a well-known antioxidant found in red wine, called resveratrol, may benefit heart tissue by limiting the effects of a condition called cardiac fibrosis.

8 Dec 2004

Thiazolidinedione (TZD) class of anti-diabetic drugs may be a potential targeted therapy for myeloma patients

In laboratory tests on multiple myeloma cells, University of Rochester researchers found that this type of cancer expresses a protein that makes it an easy target for an existing class of diabetes drugs. After more investigation, they hope the discovery will lead to a new, targeted therapy for myeloma patients.

8 Dec 2004

Transplanted bone marrow cells reduce liver fibrosis in mice

Transplanted bone marrow cells can reduce carbon tetrachloride-induced liver fibrosis in mice and significantly improve their survival rates, according to a new study

8 Dec 2004

Accumulated exposure to lead may be an important but unrecognized risk for developing cataracts in men

Lead continues to pose a significant public health problem in spite of substantial reductions in lead exposure in the United States in the recent past, according to background information in the article.

8 Dec 2004

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.

7 Dec 2004

Combination of thalidomide and dexamethasone may be a promising treatment for multiple myeloma

The combination of two pills -- thalidomide and dexamethasone -- may be an effective alternative to the intravenous chemotherapy commonly prescribed to patients with multiple myeloma, according to a large collaborative study conducted by the Eastern Cooperative Oncology Group and led by a Mayo Clinic investigator.

7 Dec 2004

Measuring bone marrow fat can better predict weakening of bones

BMD measurement with DEXA is presently the most commonly used parameter for determining bone weakening. Researchers have long questioned whether there may be other measurable bone components that influence mechanical stability of bone.

7 Dec 2004

Human parathyroid gland most likely evolved from the gills of fish

The human parathyroid gland, which regulates the level of calcium in the blood, probably evolved from the gills of fish, according to researchers from King's College London.

6 Dec 2004

Thalidomide shows promise in fighting myeloma

Thalidomide, a drug often used to treat symptoms of leprosy and in testing to fight HIV, is now demonstrating activity in fighting a common cancer that occurs in bone marrow, myeloma.

6 Dec 2004

New advances in sickle cell disease

Excruciating pain episodes, recurrent pneumonias, strokes, severe infections, chronic hemolytic anemia, and secondary pulmonary hypertension are common complications of sickle cell disease, a life-threatening inherited defect in blood that causes normally disc-shaped red blood cells to take on a sickle shape.

6 Dec 2004

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Modern research is delving deep into the human genome to find the answers to medical mysteries and, hopefully, cures for the most deadly diseases. According to four new studies presented during the 46th Annual Meeting of the American Society of Hematology

5 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

A new treatment for an incurable blood disorder proves a worse option for patients' health than an older treatment, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Genetic target found for pediatric leukemia

A molecular target newly discovered by scientists at two prestigious research institutes may pave the way for new treatments that could combat an aggressive form of leukemia, according to a study to be presented today during the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004